IDEAYA Biosciences, Inc. 8-K

What Happened

• IDEAYA Biosciences, Inc. announced a registered public offering that closed on June 10, 2026. The company sold a total of 7,222,225 shares of common stock (including the full exercise of the underwriters’ option) and issued pre‑funded warrants to purchase 5,555,576 shares. The public offering price was $27.00 per share (and $26.9999 per pre‑funded warrant); IDEAYA received net proceeds of about $323.6 million after underwriting discounts, commissions and estimated offering expenses.

Key Details

• Offering closed June 10, 2026; underwriting agreement dated June 8, 2026 with J.P. Morgan, Jefferies, TD Securities, UBS and Cantor Fitzgerald as representatives.
• Shares sold: 7,222,225 common shares (includes 1,666,669 additional shares from full exercise of 30‑day underwriters’ option).
• Pre‑Funded Warrants: 5,555,576 pre‑funded warrants issued; each warrant exercisable until fully exercised, subject to an ownership limitation; nominal exercise price $0.0001.
• Underwriter purchase price to company: $25.38 per share and $25.3799 per pre‑funded warrant; public price $27.00 (warrant price $26.9999).
• Company and its directors/officers subject to a customary 60‑day lock‑up restricting sales without underwriters’ consent. Legal opinion on validity of the securities is included (Latham & Watkins LLP).

Why It Matters

• This offering materially increases IDEAYA’s cash position (net proceeds ~ $323.6M), strengthening its financial flexibility to fund operations, clinical programs and strategic priorities.
• The use of pre‑funded warrants indicates some investors wanted to limit immediate share ownership; these instruments convert to common stock upon exercise (nominal exercise price) and may dilute future holders once exercised.
• Lock‑up restrictions temporarily limit insider selling, which can reduce short‑term share supply but does not prevent future dilution from warrant exercises.